2023 Impact Report
Discoveries made through desmoid tumor research can potentially have an impact on common cancers such as breast, colon, ovarian, and others. Highlights:
NEW FDA-Approved Drug OGSIVEO (nirogacestat) First drug with desmoid tumor indication
1
1
NEW Desmoid Tumor Cell Line
Direct Requests for Support from Patients & Caregivers 136
3
Mental Health Webinars Created to support patients
2023 DTRF-Funded Research Grants
2
6
Actively Recruiting Clinical Trials
Medical Institutions and Industry Partners Represented at DTRF Research Workshop
Desmoid Tumor Natural History Study Poster won category award at 2023 Connective Tissue Oncology Society Conf.
1
30
Recorded Scientific/Educational Presentations Created to support patients
Registrants at the DTRF Annual
8
Together We Will Weekend 163
CME-Accredited Programs Launched
4
NEW Set of ICD-10 Codes Specific to desmoid tumors
1
International Medical Advisory Board Members Guiding DTRF's research priorities
Cases Presented at DTRF Int’l Virtual Tumor Boards
12
32
I have never seen a group of people able to mobilize companies and the FDA like this!! JEAN PATY, PHD VP, PATIENT CENTERED ENDPOINTS, IQVIA
As we uncover answers , we work tirelessly to provide patients and caregivers with the resources, information, and opportunities needed to be informed advocates in their care.
We are undaunted.
Made with FlippingBook - professional solution for displaying marketing and sales documents online